I do believe the legislation can work. It's premature to conclude otherwise. We're making a sincere effort here to explore possible changes and improvements to the regime. Judging from all of the discussions that we've had to date, not much will happen because of a lack of money. Basically, it boils down to a question of funding.
Mention is often made of the regime's regulatory impediments. All of the obstacles that we've talked about are far more serious than those faced by generic drug companies when they wish to market a generic version of a patented drug. Companies manage to overcome these obstacles daily.
It really comes down to a question of incentives and it's not up to Industry Canada to...I don't know what to tell you. The regime was set up, but it is not being funded.